These findings suggest that the long-acting formulation of pegmolesatide can achieve an effective anemia correction and desirable Hb target stabilization with fewer dose adjustments, which may reduce the treatment gap for NDD renal anemia. This evidence concerns the gene GSTM1 and Neurodevelopmental delay.